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IN OBSERVATIONAL STUDIES OFwomen with and without exist-ing coronary heart disease (CHD),the use of postmenopausal hor-
mone therapy is associated with a
reduced risk of CHD events.1 In con-
trast, clinical trials have shown no
benefit and some trials have suggested
an increased risk of CHD during the
first year after randomization.2,3 The
Women’s Health Initiative (WHI)
reported a hazard ratio (HR) for CHD
of 0.95 (95% confidence interval [CI],
0.70-1.16) in the trial of conjugated
equine estrogens (CEE) and an HR of
1.24 (95% CI, 1.00-1.54) in the trial
of CEE plus medroxyprogesterone
acetate (CEEMPA).3,4 While obser-
vational studies have evidently overes-
timated benefit due to confounding,
selection biases, and other limita-
tions,5,6 an additional source of dis-
crepancy may be the timing of initia-
tion of hormone therapy in relation to
the underlying state of the vasculature.
Some investigators have hypothesized
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Context The timing of initiation of hormone therapy may influence its effect on car-
diovascular disease.
Objective To explore whether the effects of hormone therapy on risk of cardiovas-
cular disease vary by age or years since menopause began.
Design, Setting, and Participants Secondary analysis of the Women’s Health Ini-
tiative (WHI) randomized controlled trials of hormone therapy in which 10 739 post-
menopausal women who had undergone a hysterectomy were randomized to con-
jugated equine estrogens (CEE) or placebo and 16 608 postmenopausal women who
had not had a hysterectomy were randomized to CEE plus medroxyprogesterone ac-
etate (CEEMPA) or placebo. Women aged 50 to 79 years were recruited to the study
from 40 US clinical centers between September 1993 and October 1998.
MainOutcomeMeasures Statistical test for trend of the effect of hormone therapy
on coronary heart disease (CHD) and stroke across categories of age and years since
menopause in the combined trials.
Results In the combined trials, there were 396 cases of CHD and 327 cases of stroke in
the hormone therapy group vs 379 cases of CHD and 239 cases of stroke in the placebo
group. For women with less than 10 years since menopause began, the hazard ratio (HR)
for CHD was 0.76 (95% confidence interval [CI], 0.50-1.16); 10 to 19 years, 1.10 (95%
CI, 0.84-1.45); and 20 or more years, 1.28 (95% CI, 1.03-1.58) (P for trend=.02). The
estimated absolute excess risk for CHD for women within 10 years of menopause was −6
per 10 000 person-years; for women 10 to 19 years since menopause began, 4 per 10 000
person-years; and for women 20 or more years from menopause onset, 17 per 10 000
person-years. For the age group of 50 to 59 years, the HR for CHD was 0.93 (95% CI,
0.65-1.33) and the absolute excess risk was −2 per 10 000 person-years; 60 to 69 years,
0.98 (95% CI, 0.79-1.21) and −1 per 10 000 person-years; and 70 to 79 years, 1.26 (95%
CI,1.00-1.59)and19per10000person-years (P for trend=.16).Hormonetherapy increased
the risk of stroke (HR, 1.32; 95% CI, 1.12-1.56). Risk did not vary significantly by age or
time since menopause. There was a nonsignificant tendency for the effects of hormone
therapy on total mortality to be more favorable in younger than older women (HR of
0.70 for 50-59 years; 1.05 for 60-69 years, and 1.14 for 70-79 years; P for trend=.06).
Conclusions Women who initiated hormone therapy closer to menopause tended
to have reduced CHD risk compared with the increase in CHD risk among women
more distant from menopause, but this trend test did not meet our criterion for sta-
tistical significance. A similar nonsignificant trend was observed for total mortality but
the risk of stroke was elevated regardless of years since menopause. These data should
be considered in regard to the short-term treatment of menopausal symptoms.
Trial Registration clinicaltrials.gov Identifier: NCT00000611
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that estrogen may delay the onset of
the earliest stages of atherosclerosis,
which are more likely to be present in
younger women, but it may be ineffec-
tive or even trigger events in the pres-
ence of existing advanced lesions such
as those found in older women.7 The
potential existence of a window of
opportunity to reduce cardiovascular
disease is supported by animal and
laboratory studies.6
Compared with observational stud-
ies of hormone therapy use among
healthy women such as the Nurses’
Health Study, most women in the ran-
domized hormone trials were older and
the majority commenced study hor-
monesmore than a decade after meno-
pause began.3,4,8 Subgroup analyses in
the 2 WHI trials of hormone therapy
suggested a nonsignificant reduction in
risk of CHD in women aged 50 to 59
years in the trial of CEE4 or in women
with less than 10 years since meno-
pause in the trial of CEEMPA.3 Risk
of stroke did not appear to be reduced
in these subgroups.9,10 The numbers of
events in the subgroups in the indi-
vidual trials were too small to provide
definitive answers but the similar di-
rection of the findings supports the idea
that pooling the trials could yield clearer
answers.
In this secondary analysis, statisti-
cal power was improved by the use of
techniques that allow combining the
trial data to examine trends in the ef-
fects of hormone therapy on CHD and
stroke across categories of age and years
since menopause. These results could
apply to a population similar to the
women enrolled in the WHI trials,
which included 40% of women taking
unopposed estrogen (CEE) or pla-
cebo and 60% of women taking estro-
genplus progestin (CEEMPA)or pla-
cebo. Total mortality and a predefined
global index were examined to cap-
ture the overall effects of hormone
therapy on disease outcomes. Com-
bined hormone therapy trial analyses
and subgroup analyses by agewere pre-
specified in the WHI protocol; other
analyseswere not prespecified. The sub-
group and secondary analyses are ex-
ploratory; however, given that these are
the best available data, the potential
clinical implications of our findings also
are examined.
METHODS
Study Participants and Outcomes
The WHI trials enrolled 27 347 pre-
dominantly healthy postmenopausal
women aged 50 to 79 years from Sep-
tember 1993 to October 1998 at 40 US
clinical centers based on hysterec-
tomy status. Of these women, 10 739
had undergone a hysterectomy and
were randomized to 0.625mg/d of CEE
or placebo and 16 608 had not had a
hysterectomy and were randomized to
0.625 mg/d of CEE plus 2.5 mg/d of
MPAor placebo.Details have been pub-
lished elswhere.11,12
The trials were reviewed and ap-
proved by the institutional review
boards at each clinical center and all
participants provided written in-
formed consent. All outcomeswere cen-
trally adjudicated. The main out-
comes for the current analyses were
CHD (defined as nonfatal myocardial
infarction, CHD death, or silent myo-
cardial infarction) and stroke. Other
outcomes were mortality and a global
index (defined as the first occurrence
of CHD, stroke, pulmonary embo-
lism, breast cancer, colorectal cancer,
endometrial cancer [CEEMPA trial
only], hip fracture, or death from other
causes) used for trialmonitoring. Clini-
cal events that were self-reported by
participants prior to unblinding at trial
closure and subsequently adjudicated
were included. Due to the compressed
timeline for the initial publications,3,11
13 additional adjudicated cases each of
CHD and stroke from the CEEMPA
trial were available for this analysis.
Statistical Analysis
Age at menopause was defined by the
age atwhich awoman last had anymen-
strual bleeding, bilateral oophorec-
tomy, or began usingmenopausal hor-
mone therapy. For hysterectomy
without bilateral oophorectomy, the age
at menopause was the age at which a
woman either began using hormone
therapy or first had vasomotor symp-
toms (ie, hot flashes, night sweats). For
women who had a hysterectomy with-
out bilateral oophorectomy at age 50
years or older but no use of hormone
therapy or symptoms, the age at meno-
pause was defined as the age when the
hysterectomywas performed. If the al-
gorithm defined an age at menopause
as older than 60 years, it was recoded
as 60 years. Anymisclassification of age
at menopause is likely to be nondiffer-
ential and would tend to bias the re-
sults toward the null. Age at meno-
pause could not be defined (due to
missing values) in 1420 (8.5%)women
who had not had a hysterectomy and
in 1610 (15%) women who had a hys-
terectomy. These women were ex-
cluded from the years since meno-
pause analyses, which included 24 317
participants.
Study participants completed a ques-
tionnaire at baseline that included a
probe for the presence of vasomotor
symptoms (hot flashes or night sweats)
during the prior 4weeks. If present, par-
ticipants were asked how bothersome
the symptom was. Mild indicated that
the symptom did not interfere with
usual activities; moderate, the symp-
tom interfered somewhatwith usual ac-
tivities; and severe, the symptom was
so severe that usual activities could not
be performed.
Event rate comparisons were based
on the intent-to-treat principle using
failure time methods. For a given out-
come, the time to event was the num-
ber of days from randomization to the
first diagnosis of the designated event.
Comparisons of outcomes are pre-
sented as HRs and 95% CIs stratified
by prior cardiovascular disease (de-
fined as history of myocardial infarc-
tion, angina, coronary or carotid
revascularization, stroke, transient
ischemic attack, or peripheral arterial
disease) and randomization status in
the Dietary Modification Trial. The
stratified models allow for flexible
(and possibly different) hazard func-
tions between strata and hence more
accurately capture the effects of hor-
mone therapy. Preliminary analyses
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showed no striking differences in HRs
across categories of age or years since
menopause in women with and with-
out prior cardiovascular disease, or
in unadjusted models and models
adjusted for baseline risk factors (race/
ethnicity, education, physical activity,
prior hormone use, body mass index
[calculated as weight in kilograms
divided by height in meters squared],
left ventricular hypertrophy by elec-
trocardiographic criteria, current
smoking, hypertension, treated diabe-
tes, and treated high serum cholesterol
level). Therefore, the results of unad-
justed models for all women are pre-
sented. For consistency with the dis-
play of HRs within categories of age or
years since menopause, the estimated
absolute excess risks were obtained by
applying the HR in each category to
the observed annualized incidence in
the placebo group. The 95% CIs were
calculated by bootstrap methods. Like-
lihood ratio tests were used to test for
differences between the age categories
and the categories for years since
menopause.
The primary analyses of this study
were based on the 2 trials combined.
Separate tests for trend were per-
formed to examine differences in hor-
mone effects across 3 preselected, coded
categories of age (50-59, 60-69, 70-79
years) or years sincemenopause (10,
10-19, and 20) using Cox regres-
sionmodel interaction terms.13 The tests
stratified the baseline disease rates for
theCEE andCEEMPAcohorts by ac-
tive vs placebo (4 strata), while leav-
ing the form of the (marginal) HR for
hormone therapy unspecified as a func-
tion of time from randomization. The
marginal HR dependence on age or
years since menopause also was unre-
stricted through the separate inclu-
sion for each trial cohort of indicator
variables for the upper 2 age group cat-
egories or years since menopause cat-
egories in the log HR models.
The models included regression
terms for interaction between cohorts
and coded indicator variables for the 3
categories of age or years since meno-
pause. The categories were assigned an
ordinal number (1, 2, 3) and then the
resulting variable was fitted as a con-
tinuous linear variable in the riskmod-
els. Interaction terms between age or
years since menopause and active vs
placebo groups tested whether there
were differential effects of hormone
therapy as a function of age or years
since menopause. These models allow
the data for the 2 trials to be com-
bined because they do not make as-
sumptions about baseline risk or the
overall treatment effect of hormone
therapy in each of the trials. Analyses
also were performed for each of the
trials separately. The method used to
test HR interactions differs slightly
from that used in previous publica-
tions,3,4,12 in that age and years since
menopause aremodeled as coded rather
than as continuous variables. Models
using coded variables are likely to be
less sensitive to the effects of extreme
values but may occasionally yield dif-
ferent results than the models using
continuous variables.
Other analyses were defined for the
purposes of this study based on a priori
considerations of biologic plausibil-
ity. These included analyses aimed at
separating out the effects of age and
years since menopause by including
terms for both variables as well as an
interaction term. Models allowing the
HRs and baseline disease incidence to
vary by risk factor status were used to
directly compare the HRs between the
2 trials. Further analyses testedwhether
the trends in the effect of hormone
therapy by age or years since meno-
pause varied with several factors po-
tentially related to hormone status (eg,
prior hormone use [never, past, cur-
rent]; oophorectomy; presence or ab-
sence of vasomotor symptoms [never,
mild, moderate or severe] at base-
line). Tests were performed by includ-
ing appropriate additional product in-
teraction terms (eg, 3-way interaction
of vasomotor symptoms, age, and hor-
mone therapy treatment effect). The
possibility that interactions between age
and years since menopause could vary
by duration of hormone therapywas ex-
amined in models and included addi-
tional product terms for duration of
therapy. Adherence-adjusted sensitiv-
ity analyses censored a woman’s event
history 6 months after becoming non-
adherent (defined as taking 80% of
study drugs or completely stopping
use). Analyses of the effects of hor-
mone therapy also were performed by
years since last exposure to either en-
dogenous or exogenous hormones
(years since menopause or last use of
hormone therapy).
Statistical tests were undertaken at
the .01 level to partially account for
multiple testing issues and the post
hoc nature of some of the tests. Forty-
two tests for trend, 33 additional
interaction tests, and 62 comparisons
of HRs were performed (a total of 137
tests). Two P values were significant
(1-2 were expected by chance). For
consistency with previous WHI stud-
ies, HRs and 95% CIs were used. An
HR of less than 1 favored hormone
therapy and greater than 1 favored
placebo. The 95% CIs were estimated
in 182 subgroups. Of these 182, 19
did not include 1 (9 were expected by
chance). Statistical analyses were per-
formed using SAS version 9 (SAS
Institute Inc, Cary, NC).
RESULTS
Baseline Characteristics
As previously reported, women in the
CEE trial had a more adverse cardio-
vascular risk profile thanwomen in the
CEEMPA trial, with a higher preva-
lence of obesity, left ventricular hyper-
trophy by electrocardiogram, hyper-
tension, diabetes, hypercholesterolemia,
and prior history of cardiovascular dis-
ease.3,4,9-12 Previous use of postmeno-
pausal hormones was reported by 61%
and 41% of women with and without
a prior bilateral oophorectomy, respec-
tively, in the CEE trial compared with
26% of womenwho had not had a hys-
terectomy in the CEEMPA trial. Va-
somotor symptoms were reported in
43% (17%moderate or severe) of CEE
participants and 38% (12% moderate
or severe) of CEEMPA participants,
andweremore frequent inwomenwho
initiated therapy closer to the onset of
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menopause (TABLE 1 and TABLE 2).
Coronary risk factors (except smok-
ing) andprior cardiovascular disease in-
creased markedly with increasing age
and years since menopause (data not
shown).
Overall Effects of Hormone
Therapy (All Participants)
Consistent with previous WHI stud-
ies,3,4 hormone therapy did not reduce
overall risk of CHD (TABLE 3). As
before, the HR for CHD was lower
when participants were taking CEE
than when taking CEEMPA (0.95
vs 1.23; P= .02 after adjusting for
risk factors).4 Risk of stroke was
increased (HR, 1.32; 95% CI, 1.12-
1.56) in the combined trials, with no
difference between the individual
trials. Individual trial results were
similar to those described in previous
publications using centrally coded
data.3,4,9,10,12 Estimated absolute excess
risks per 10 000 person-years were
approximately 3 for CHD, 9 for stroke,
1 for total mortality, and 14.5 for the
global index in the combined trials,
under a constant HR model for each
trial.
Effects of Hormone Therapy
by Age at Randomization
The numbers of events increased with
increasing age but there was no statis-
tically significant additional effect of
hormone therapy by age for any out-
c ome in t h e comb in ed t r i a l s
(TABLE 4). The trends in HRs for CHD
appeared to be somewhat more pro-
nounced in women without prior car-
diovascular disease with HRs of 0.91,
0.97, and 1.33 across the 3 age groups
(535 cases; P for trend=.10) compared
with 0.99, 0.98, and 1.12 in women
with prior cardiovascular disease
Table 1. Selected Baseline Characteristics of Participants in the Trial of Conjugated Equine Estrogens (CEE) (n = 10 739)*
No. (%) of Participants
Randomization
Assignment Age at Randomization Years Since Menopause
CEE
(n = 5310)
Placebo
(n = 5429)
50-59 y
(n = 3310)
60-69 y
(n = 4852)
70-79 y
(n = 2577)
10
(n = 1643)
10-19
(n = 2936)
20
(n = 4550)
Years since menopause
10 826 (15.6) 817 (15.0) 1237 (37.4) 406 (8.4) 0
10-19 1436 (27.0) 1500 (27.6) 1030 (31.1) 1564 (32.2) 342 (13.3)
20 2231 (42.0) 2319 (42.7) 524 (15.8) 2150 (44.3) 1876 (72.8)
Age group, y
50-59 1237 (75.3) 1030 (35.1) 524 (11.5)
60-69 406 (24.7) 1564 (53.3) 2150 (47.3)
70-79 0 342 (11.6) 1876 (41.2)
Vasomotor symptoms
None 2962 (55.8) 3004 (55.3) 1245 (37.6) 2850 (58.7) 1871 (72.6) 770 (46.8) 1834 (62.4) 3067 (68.9)
Mild 1377 (25.9) 1442 (26.6) 1132 (34.2) 1243 (25.6) 444 (17.2) 531 (32.3) 686 (23.3) 955 (21.4)
Moderate or severe 913 (17.2) 917 (16.9) 903 (27.3) 706 (14.6) 221 (8.6) 342 (20.8) 416 (14.1) 528 (11.8)
Prior use of hormone therapy
Never 2769 (52.1) 2770 (51.0) 1671 (50.5) 2498 (51.5) 1370 (53.2) 835 (50.8) 1383 (47.1) 1711 (37.6)
Past 1871 (35.2) 1948 (35.9) 935 (28.2) 1247 (36.0) 626 (24.3) 452 (27.5) 1036 (35.3) 2331 (51.2)
Current 669 (12.6) 708 (13.0) 359 (18.0) 603 (12.4) 389 (15.1) 356 (21.7) 516 (17.6) 505 (11.1)
Duration of prior hormone
therapy use, y
5 1352 (25.5) 1412 (26.0) 935 (28.2) 1203 (24.8) 626 (24.3) 579 (35.2) 786 (26.8) 1399 (30.7)
5-9 469 (8.8) 515 (9.5) 359 (10.8) 433 (8.9) 192 (7.5) 223 (13.6) 295 (10.0) 466 (10.2)
10 720 (13.6) 732 (13.5) 345 (10.4) 718 (14.8) 389 (15.1) 6 (0.4) 472 (16.1) 974 (21.4)
Prior bilateral oophorectomy
No 2973 (56.0) 2917 (53.7) 2006 (60.6) 2578 (53.1) 1306 (50.7) 1216 (74.0) 1473 (50.2) 1816 (39.9)
Yes 1938 (36.5) 2111 (38.9) 1128 (34.1) 1904 (39.2) 1017 (39.5) 334 (20.3) 1279 (43.6) 2431 (53.4)
Hormone therapy use among
participants with bilateral
oophorectomy
Never 737 (38.0) 829 (39.3) 352 (31.2) 755 (39.7) 459 (45.1) 104 (31.1) 537 (42.0) 920 (37.8)
Past 894 (46.1) 968 (45.9) 508 (45.0) 870 (45.7) 484 (47.6) 132 (39.5) 491 (38.4) 1239 (51.0)
Current 307 (15.8) 313 (14.8) 268 (23.8) 278 (14.6) 74 (7.3) 98 (29.3) 250 (19.5) 271 (11.2)
Hormone therapy use among
participants without
bilateral oophorectomy
Never 1783 (60.1) 1699 (58.2) 1209 (60.3) 1525 (59.2) 752 (57.6) 679 (55.8) 755 (51.3) 667 (36.7)
Past 861 (29.0) 857 (29.4) 485 (24.1) 767 (29.8) 466 (35.7) 298 (24.5) 477 (32.4) 943 (51.9)
Current 324 (10.9) 359 (12.3) 312 (15.6) 283 (11.0) 88 (6.7) 239 (19.7) 241 (16.4) 203 (11.1)
*The numbers may not add up to the total because of missing data.
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(214 cases; P for trend=.72); however,
these trends did not differ significantly
(P for interaction=.54). There were no
significant increases in risk due to
hormone therapy for any outcome at
ages 50 to 59 years, but increases
in risk for CHD, stroke, and global
index events in some older age catego-
ries were noted. There was a reduction
in total mortality in the age group of
50 to 59 years (HR, 0.70; 95% CI,
0.51-0.96), with a nonsignificant trend
for increasing HRs across age groups
(P=.06). In adjusted models, the HRs
of CHD (P= .04) and global index
events (P=.04) were nonsignificantly
lower in the age group of 50 to 59
years for women taking CEE com-
pared with women taking CEEMPA
but HRs were comparable at older
ages (results not shown). The HR for
the global index increased with age in
the CEE trial (P for trend=.01). How-
ever, the trend statistics for CHD and
global index did not differ between the
trials.
Effects of Hormone Therapy
by Years Since Menopause
The HR for CHD was 0.76 in women
with less than 10 years since meno-
pause, 1.10 for women with 10 to less
than20years sincemenopause, and1.28
forwomenwithmore than20years since
menopause (P for trend=.02;TABLE 5).
Hormone therapy increased the risk of
CHD in women with 20 or more years
since menopause (HR, 1.28; 95% CI,
1.03-1.58). Inwomenwithout prior car-
diovascular disease, the HRs across cat-
egories of years since menopause were
0.78, 1.10, and 1.35 (464 cases; P for
trend=.02) and inwomenwithprior car-
diovascular disease theywere 0.59, 1.08,
and 1.14 (180 cases; P for trend=.44);
these trends did not differ significantly
(P for interaction=.68). In contrast to
CHD, the effect of hormone therapy on
stroke risk was similar in all categories
of years since menopause, with a HR of
1.77 (95%CI, 1.05-2.98) inwomenwith
less than 10 years since menopause. In
women with less than 10 years since
menopause without prior cardiovascu-
lar disease, the HR for stroke was 1.64;
after excluding women older than 60
years, theHRattenuated to 1.23 (all 95%
CIs included 1). There were no signifi-
cant differences in the HRs between the
trials inanycategoryof years sincemeno-
pause in the adjustedmodels (results not
shown), and the trend statistics for treat-
ment effects by years since menopause
also were similar for all outcomes.
Estimated Absolute Excess Risk
The combination of low incidence rates
and modest HRs at ages 50 to 59 years
led to low or no absolute excess risks of
CHD, stroke, total mortality, or global
index events due tohormone therapy in
that agegroup(FIGURE1).With increas-
ing age, the higher incidence rates and
largerHRs yielded progressively larger
estimated absolute excess risks due to
hormone therapy.At ages50 to59years,
there were 10 fewer deaths per 10 000
person-years compared with 16 addi-
tional deaths at ages 70 to 79 years
Table 2. Selected Baseline Characteristics of Participants in the Trial of Conjugated Equine Estrogens Plus Medroxyprogesterone Acetate
(CEE  MPA) (n = 16 608)*
No. (%) of Participants
Randomization Assignment Age at Randomization Years Since Menopause
CEEMPA
(n = 8506)
Placebo
(n = 8102)
50-59 y
(n = 5522)
60-69 y
(n = 7510)
70-79 y
(n = 3576)
10
(n = 5494)
10-19
(n = 6041)
20
(n = 3653)
Years since menopause
10 2782 (32.7) 2712 (33.5) 4092 (74.1) 1402 (18.7) 0
10-19 3947 (35.8) 2994 (37.0) 831 (15.0) 4320 (57.5) 890 (24.9)
20 1850 (21.7) 1803 (22.3) 55 (1.0) 1145 (15.2) 2453 (68.6)
Age group, y
50-59 4092 (74.5) 831 (13.8) 55 (1.5)
60-69 1402 (25.5) 4320 (71.5) 1145 (31.3)
70-79 0 890 (14.7) 2453 (76.2)
Vasomotor symptoms
None 5162 (60.7) 4928 (60.8) 2298 (41.6) 4974 (66.2) 2818 (78.8) 2411 (43.8) 4113 (68.0) 2827 (77.3)
Mild 2190 (25.8) 2115 (26.1) 1947 (35.3) 1804 (24.0) 554 (15.5) 1945 (32.3) 1384 (22.9) 628 (17.1)
Moderate or severe 1072 (12.6) 974 (12.0) 1224 (22.2) 650 (8.7) 172 (4.8) 1138 (20.7) 544 (9.0) 198 (5.4)
Prior use of hormone therapy
Never 6277 (73.8) 6020 (74.3) 3937 (71.3) 5683 (75.7) 2677 (74.9) 3803 (69.2) 4558 (75.5) 2516 (68.9)
Past 1671 (19.6) 1588 (19.6) 1033 (18.7) 1418 (18.9) 808 (22.6) 1109 (20.2) 1126 (18.6) 1024 (28.0)
Current 554 (6.5) 491 (6.1) 552 (10.0) 403 (5.4) 90 (2.5) 581 (10.6) 354 (5.9) 110 (3.0)
Duration of prior hormone
therapy use, y
5 1539 (18.1) 1470 (18.1) 1200 (21.7) 1239 (16.5) 570 (15.9) 1363 (24.8) 917 (15.2) 729 (20.0)
5-9 427 (5.0) 356 (4.4) 302 (5.5) 328 (4.4) 153 (4.3) 322 (5.9) 282 (4.7) 179 (4.9)
10 263 (3.1) 255 (3.1) 83 (1.5) 259 (3.4) 176 (4.9) 5 (0.1) 284 (4.7) 229 (6.3)
*The numbers may not add up to the total because of missing data.
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(P=.03).Thepatternof increasingabso-
lute excess risks across age categories
was observed in both trials. In theCEE
trial, the higher absolute excess risks
of death and global index events in the
oldest age groupappeared todiffer from
the reduced risks at ages 50 to 59 years
(P=.02 and P=.01, respectively).
In women with less than 10 years
sincemenopause, there were no appar-
ent effects of hormone therapy on ab-
solute excess risks of CHD, total mor-
tality, or global index in the combined
trials (FIGURE 2). However, there were
excess risks of stroke in each category
for years sincemenopause, and the 95%
CI excluded 1 for the category of
women with less than 10 years since
menopause. Increasing absolute ex-
cess risks were observed for CHD, total
mortality, and global index events in
women more distant frommenopause
but only the 17 additional CHD events
in women with 20 or more years since
menopause approached statistical sig-
nificance compared with the reduc-
tion of 6 events inwomenwith less than
10 years sincemenopause (P=.03). The
patterns across menopause categories
were consistent across the 2 trials.
Additional Analyses
There was a high correlation between
ageandyears sincemenopause (r=0.71).
The nonsignificant modification of age
relative to the effect of hormone therapy
on CHD in the combined trials (P for
trend=.16) became even weaker with
additional adjustment on years since
menopause (P for trend=.83). The re-
lationship of years since menopause to
the HR for CHD also was attenuated
(from P=.02 to P=.07) with additional
adjustment for age.
There were no significant trends for
hormonetherapybyyearssincelastexpo-
sure tohormones (endogenousor exog-
enous) andnosignificant interactionsof
priorhormoneuseoroophorectomysta-
tus with in-trial hormone effects by age
or by years sincemenopause. However,
vasomotor symptoms at baseline may
have influenced the results for CHD by
bothageandyears sincemenopause.The
possible 3-way interactions of vasomo-
tor symptoms with hormone therapy
effects on the HR trend by age (P=.04)
and by years since menopause (P=.06)
appeared tobedue to trendsacross these
categories in the 12% to 17% of women
inthe trialswithmoderateorseverevaso-
motor symptoms (P for trend .01;
TABLE 6 and TABLE 7). There were not
any similar trends in thewomenwithno
or mild vasomotor symptoms at base-
line (data not shown). There were no
apparent effects of hormone therapy on
CHD in women with vasomotor symp-
toms aged 50 to 59 years or in women
with less than 10 years since meno-
pause. Increased risks for CHD, stroke,
and global index events were seen in
women aged 70 to 79 years at baseline
and for CHD and global index events in
women with 20 or more years since
menopause.Thefindingsweresimilar for
women taking CEE and CEEMPA
(data not shown).
Thevasomotor symptoms in theolder
women appeared to be related to hor-
monal factors to a similar extent as those
inyoungerwomenbecausea largemajor-
ity reported their first symptoms start-
ingatmenopause.Thevasomotor symp-
toms responded to hormone therapy in
the trial to a similar extent, with the
exception of a lesser response of night
sweats toCEEMPAinwomenaged70
to79yearsorwith20ormoreyears since
menopause (data not shown). Risk fac-
tors for CHD tended to bemore adverse
in the women with vasomotor symp-
toms in each age group and in each cat-
egory for years since menopause. How-
ever, the resultsdidnot changewhen the
analyses for interaction were repeated
with adjustment for risk factors. Simi-
larly, adjustment for adherence to study
pills did not change the results.
Sensitivity analyses that censored the
data when awoman became nonadher-
ent generally increased theHRs for out-
comes but did not show any substan-
Table 3. Overall Cardiovascular and Global Index Events
No. of Cases (Annualized %)*
HR
(95% CI)†
Estimated Absolute
Excess Risk per
10 000 Person-Years
(95% CI)‡
Hormone
Therapy
(n = 13 816)
Placebo
(n = 13 531)
Combined Trials
CHD§ 396 (0.46) 379 (0.44) 1.07 (0.92 to 1.23) 3.1 (−2.6 to 9.4)
Stroke 327 (0.38) 239 (0.29) 1.32 (1.12 to 1.56) 9.3 (3.4 to 15.1)
Total mortality 546 (0.63) 528 (0.63) 1.02 (0.90 to 1.15) 1.2 (−6.0 to 8.6)
Global index  1601 (1.94) 1467 (1.81) 1.08 (1.00 to 1.16) 14.5 (1.7 to 28.2)
CEE Trial
CEE
(n = 5310)
Placebo
(n = 5429)
CHD§ 201 (0.54) 217 (0.57) 0.95 (0.78 to 1.16) −2.9 (−13.2 to 8.3)
Stroke 168 (0.45) 127 (0.33) 1.33 (1.05 to 1.68) 10.9 (1.6 to 20.3)
Total mortality 297 (0.79) 292 (0.75) 1.04 (0.88 to 1.22) 3.2 (−8.9 to 16.0)
Global index  747 (2.06) 744 (2.01) 1.02 (0.92 to 1.13) 4.0 (−13.0 to 26.1)
CEE + MPA Trial
CEEMPA
(n = 8506)
Placebo
(n = 8102)
CHD§ 195 (0.41) 153 (0.34) 1.23 (0.99 to 1.53) 7.8 (−0.3 to 16.0)
Stroke 159 (0.33) 112 (0.25) 1.31 (1.03 to 1.68) 7.8 (0.8 to 14.2)
Total mortality 249 (0.52) 236 (0.52) 1.00 (0.83 to 1.19) 0 (−9.6 to 10.0)
Global index  854 (1.84) 723 (1.65) 1.13 (1.02 to 1.25) 21.5 (4.3 to 39.6)
Abbreviations: CEE, conjugated equine estrogens; CHD, coronary heart disease; CI, confidence interval; HR, hazard
ratio; MPA, medroxyprogesterone acetate.
*Annualized percentage defined as cases per 100 person-years.
†Cox regression model stratified according to age (50-54, 55-59, 60-69, 70-79 years), prior cardiovascular disease,
and randomization status in the Dietary Modification Trial.
‡Calculated as [annualized percentage in placebo group  (HR in placebo group – 1)]  1000. The 95% CIs were
estimated by bootstrap methods (however, bootstrap methods may introduce some inaccuracies).
§Defined as CHD death, nonfatal myocardial infarction, or definite silent myocardial infarction (Novacode 5.1 or 5.2).
Defined as CHD, stroke, pulmonary embolism, breast cancer, colorectal cancer, endometrial cancer for CEE plus
MPA trial only, hip fracture, or death from other causes.
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tial modification of hormone effects by
age or years since menopause. Other
models suggested a time-dependent
effect of hormone therapy in the com-
bined trials for CHD (but not stroke),
with higher risks in the first 2 years and
decreasing risk thereafter (P=.01). Even
though power was limited by small
numbers of events, the direction of
time-dependent effects were similar
within categories of age or years since
menopause, and there were no inter-
actions of time-dependent effects on
HRs across the age or years sincemeno-
pause categories.
COMMENT
Although not statistically significant,
these secondary analyses suggest that
the effect of hormones on CHDmay be
modified by years sincemenopause and
by the presence of vasomotor symp-
toms, with the highest risks in women
whowere 20 ormore years sincemeno-
pause (or aged 70 years). Coronary
heart disease tended to be nonsignifi-
cantly reduced by hormone therapy in
younger women or women with less
than 10 years sincemenopause, and the
risk of total mortality was reduced in
women aged 50 to 59 years.We did not
have adequate statistical power to as-
sess outcomes in the women aged 50
to 54 years or less than 5 years since
menopause. As previously reported,
CEE appeared to be associated with
lower risk of CHD than CEEMPA.4
Importantly, the risk of stroke was not
influenced by years since menopause,
the presence of vasomotor symptoms,
or drug regimen, although therewas no
increased risk of stroke in women aged
50 to 59 years.
Our findings are consistentwith find-
ings from observational studies of the
association of years since menopause
Table 4. Cardiovascular and Global Index Events by Age at Baseline
Age Group at Randomization
P
Value
for
Trend†
50-59 y 60-69 y 70-79 y
No. of Cases
HR
(95% CI)*
No. of Cases
HR
(95% CI)*
No. of Cases
HR
(95% CI)*
Hormone
Therapy
(n = 4476)
Placebo
(n = 4356)
Hormone
Therapy
(n = 6240)
Placebo
(n = 6122)
Hormone
Therapy
(n = 3100)
Placebo
(n = 3053)
Combined Trials
CHD‡ 59 61 0.93
(0.65-1.33)
174 178 0.98
(0.79-1.21)
163 131 1.26
(1.00-1.59)
.16
Stroke 44 37 1.13
(0.73-1.76)
156 102 1.50
(1.17-1.92)
127 100 1.21
(0.93-1.58)
.97
Total mortality 69 95 0.70
(0.51-0.96)
240 225 1.05
(0.87-1.26)
237 208 1.14
(0.94-1.37)
.06
Global index§ 278 278 0.96
(0.81-1.14)
717 661 1.08
(0.97-1.20)
606 528 1.14
(1.02-1.29)
.09
CEE Trial
CEE
(n = 1637)
Placebo
(n = 1673)
CEE
(n = 2387)
Placebo
(n = 2465)
CEE
(n = 1286)
Placebo
(n = 1291)
CHD‡ 21 34 0.63
(0.36-1.09)
96 106 0.94
(0.71-1.24)
84 77 1.13
(0.82-1.54)
.12
Stroke 18 21 0.89
(0.47-1.69)
84 54 1.62
(1.15-2.27)
66 52 1.21
(0.84-1.75)
.62
Total mortality 34 48 0.71
(0.46-1.11)
129 131 1.02
(0.80-1.30)
134 113 1.20
(0.93-1.55)
.18
Global index§ 114 140 0.82
(0.64-1.05)
333 342 1.01
(0.86-1.17)
300 262 1.16
(0.98-1.37)
.01
CEE + MPA Trial
CEEMPA
(n = 2839)
Placebo
(n = 2683)
CEEMPA
(n = 3853)
Placebo
(n = 3657)
CEEMPA
(n = 1814)
Placebo
(n = 1762)
CHD‡ 38 27 1.29
(0.79-2.12)
78 72 1.03
(0.74-1.43)
79 54 1.48
(1.04-2.11)
.70
Stroke 26 16 1.41
(0.75-2.65)
72 48 1.37
(0.95-1.97)
61 48 1.21
(0.82-1.78)
.56
Total mortality 35 47 0.69
(0.44-1.07)
111 94 1.09
(0.83-1.44)
103 95 1.06
(0.80-1.41)
.19
Global index§ 164 138 1.10
(0.87-1.38)
384 319 1.15
(0.99-1.34)
306 266 1.13
(0.95-1.33)
.96
Abbreviations: CEE, conjugated equine estrogens; CHD, coronary heart disease; CI, confidence interval; HR, hazard ratio; MPA, medroxyprogesterone acetate.
*Cox regression models stratified according to prior cardiovascular disease and randomization status in the Dietary Modification Trial.
†Test for trend (interaction) using age as continuous (linear) form of categorical coded values. Cox regression models stratified according to active vs placebo and trial, including
terms for age and the interaction between trials and age.
‡Defined as CHD death, nonfatal myocardial infarction, or definite silent myocardial infarction (Novacode 5.1 or 5.2).
§Defined as CHD, stroke, pulmonary embolism, breast cancer, colorectal cancer, endometrial cancer for CEE plus MPA trial only, hip fracture, or death from other causes.
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with carotid intima-media thick-
ness.14,15 Although age and years since
menopause are highly correlated, in our
analyses years since menopause ap-
peared to influence hormone effects on
CHD somewhatmore than chronologi-
cal age. Estrogenmay have dual and op-
posing actions, retarding the earlier
stages of atherosclerosis through ben-
eficial effects on endothelial function
and blood lipids, but triggering acute
events in the presence of advanced le-
sions through procoagulant and in-
flammatory mechanisms.5,6 Our find-
ings are consistent with a neutral effect
of hormone therapy in women soon af-
ter menopause (who are likely to have
fewer complicated lesions), but pro-
gressively more unfavorable effects on
CHD risk in later years. The trends
across categories of age and years since
menopause appeared to be somewhat
stronger in womenwithout a history of
prior cardiovascular disease (al-
though this trend was not signifi-
cantly different fromwomenwith prior
cardiovascular disease, possibly due to
small numbers). It is not known why
the effects of hormone therapy on
stroke overall, and in women close to
menopause, differ from the effects of
therapy onCHD. Risk of stroke on hor-
mone therapy was elevated by 77% in
women with 10 or less years since
menopause but by a nonsignificant 13%
inwomen aged 50 to 59 years. The risk
for stroke in women with less than 10
years since menopause attenuated to a
nonsignificant increase of 23% when
those with prior cardiovascular dis-
ease and who were older than 60 years
were excluded.
This analysis of the WHI data pro-
vides some convergence with informa-
tion from observational studies, ani-
Table 5. Cardiovascular and Global Index Events by Years Since Menopause at Baseline
Years Since Menopause
P
Value
for
Trend†
10 10-19 20
No. of Cases
HR
(95% CI)*
No. of Cases
HR
(95% CI)*
No. of Cases
HR
(95% CI)*
Hormone
Therapy
(n = 3608)
Placebo
(n = 3529)
Hormone
Therapy
(n = 4483)
Placebo
(n = 4494)
Hormone
Therapy
(n = 4081)
Placebo
(n = 4122)
Combined Trials
CHD‡ 39 51 0.76
(0.50-1.16)
113 103 1.10
(0.84-1.45)
194 158 1.28
(1.03-1.58)
.02
Stroke 41 23 1.77
(1.05-2.98)
100 79 1.23
(0.92-1.66)
142 113 1.26
(0.98-1.62)
.36
Total mortality 53 67 0.76
(0.53-1.09)
142 149 0.98
(0.78-1.24)
267 240 1.14
(0.96-1.36)
.51
Global index§ 222 203 1.05
(0.86-1.27)
482 440 1.12
(0.98-1.27)
675 632 1.09
(0.98-1.22)
.82
CEE Trial
CEE
(n = 826)
Placebo
(n = 817)
CEE
(n = 1436)
Placebo
(n = 1500)
CEE
(n = 2231)
Placebo
(n = 2319)
CHD‡ 8 16 0.48
(0.20-1.17)
47 50 0.96
(0.64-1.44)
117 111 1.12
(0.86-1.46)
.15
Stroke 17 8 2.24
(0.92-5.44)
43 30 1.47
(0.92-2.35)
86 72 1.20
(0.87-1.65)
.24
Total mortality 14 21 0.65
(0.33-1.29)
63 70 0.93
(0.66-1.30)
169 152 1.16
(0.93-1.45)
.42
Global index§ 60 62 0.94
(0.65-1.36)
179 177 1.05
(0.85-1.29)
391 381 1.07
(0.92-1.23)
.63
CEE + MPA Trial
CEEMPA
(n = 2782)
Placebo
(n = 2712)
CEEMPA
(n = 3047)
Placebo
(n = 2994)
CEEMPA
(n = 1850)
Placebo
(n = 1803)
CHD‡ 31 35 0.88
(0.54-1.43)
66 53 1.23
(0.85-1.77)
77 47 1.66
(1.14-2.41)
.05
Stroke 24 15 1.58
(0.81-3.05)
57 49 1.12
(0.76-1.64)
56 41 1.35
(0.89-2.03)
.87
Total mortality 39 46 0.81
(0.52-1.24)
79 79 1.03
(0.75-1.41)
98 88 1.11
(0.83-1.49)
.93
Global index§ 162 141 1.09
(0.87-1.37)
303 263 1.17
(0.99-1.38)
284 251 1.13
(0.95-1.35)
.92
Abbreviations: CEE, conjugated equine estrogens; CHD, coronary heart disease; CI, confidence interval; HR, hazard ratio; MPA, medroxyprogesterone acetate.
*Cox regression models stratified according to prior cardiovascular disease and randomization status in the Dietary Modification Trial.
†Test for trend (interaction) using age as continuous (linear) form of categorical coded values. Cox regression models stratified according to active vs placebo and trial, including
terms for years since menopause and the interaction between trials and years since menopause.
‡Defined as CHD death, nonfatal myocardial infarction, or definite silent myocardial infarction (Novacode 5.1 or 5.2).
§Defined as CHD, stroke, pulmonary embolism, breast cancer, colorectal cancer, endometrial cancer for CEE plus MPA trial only, hip fracture, or death from other causes.
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mal studies, and laboratory studies,
which have focused mainly on the ef-
fects of estrogen onnormal coronary ar-
teries or women without clinical car-
diovascular disease.5,6,16 However,
differences remain. One observational
study examining this issue predicted a
reduced risk of CHD in healthywomen
who commenced hormone therapy
within 4 years sincemenopause, and no
effect in women with 10 or more years
since menopause,7 while our com-
bined trial data find a nonsignificant re-
duction in women starting hormone
therapy during 10 or less years since
menopause and increasing risks there-
after. Women’s Health Initiative data
suggest an advantage for CEE com-
pared with CEEMPA in regard to
CHD, but the observational data would
predict similar effects for these formu-
lations (at least for CEE with the cy-
clicalMPAmore commonly used in ob-
servational studies).1,7,16
There is also a divergence in regard
to secondary prevention, with obser-
vational study but not trial data on
women with existing disease suggest-
ing CHD benefit for hormone us-
ers.1,2,17,18 The inclusion of a small pro-
portion of womenwith prior disease in
this analysis of trial data and in simi-
lar analyses of observational study data
did not change the estimates of CHD
risk onhormone therapy by age or years
since menopause appreciably, possi-
bly because there were relatively few
such women in younger age catego-
ries, and in the older age categories the
presence of prior CHD is but one of
manyother factors contributing to risk.7
Some observational and trial data agree
in predicting early harm in women af-
ter initiation of hormone therapy.2,3,17-20
Confounding due to the healthier char-
acteristics of hormone users, and fail-
ure to account for years since hor-
mone therapy initiation, would lead to
overestimation of benefit for CHD in
observational studies, even after ad-
justing for measurable factors.5
Absolute risks may be more helpful
thanHRs to cliniciansweighing the pros
and cons of hormone therapy for par-
ticular patients. Because of low event
rates in more recently menopausal
women, the absolute excess risk will be
very small, even in the presence of some
increased relative risk due to hormone
therapy. On the other hand the higher
event rates inwomenmore distant from
menopause, together with their in-
creased HRs, translate into large abso-
lute excess risks. The low or absent ex-
cess risks of CHD in women with less
than 10 years since menopause may be
somewhat reassuring towomen consid-
ering theuse of hormones in the first few
years aftermenopause.However, the in-
creasedabsolute riskof stroke in this sub-
group (althoughnot apparent inwomen
aged 50-59 years in theCEE trial and at-
Figure 1. Estimated Absolute Excess Risk per 10 000 Person-Years by Age Group at Baseline
CHD
50-59
Age Group, y
60-69
70-79
Stroke
50-59
Age Group, y
60-69
70-79
Total Mortality
50-59
Age Group, y
60-69
70-79
Global Index
50-59
Age Group, y
60-69
70-79
Estimated Absolute Excess Risk
per 10 000 Person-Years
0 40 80 120–40
Cases per
100 Person-Years
CEE +
MPA
0.22
0.36
0.82
0.15
0.34
0.63
0.21
0.51
1.06
0.99
1.85
3.35
Placebo
0.17
0.36
0.58 †
0.10
0.24
0.52
0.30
0.47
1.01
0.89
1.64
2.99
CEE + MPA Trial
Estimated Absolute Excess Risk
per 10 000 Person-Years
0 40 80 120–40
Cases per
100 Person-Years
Hormone
Therapy
0.20
0.46
0.90
0.15
0.41
0.70
0.24
0.63
1.28
0.97
1.95
3.50
Placebo
0.22
0.48
0.72 ∗
0.13
0.27
0.55
0.34
0.60
1.14 ∗
1.01
1.83
3.06
Combined Trials
Estimated Absolute Excess Risk
per 10 000 Person-Years
0 40 80 120–40
Cases per
100 Person-Years
CEE
0.17
0.58
0.98
0.15
0.51
0.76
0.28
0.77
1.53
0.95
2.07
3.67
Placebo
0.27
0.62
0.88
0.17
0.31
0.59
0.38
0.75
1.27 †
1.15
2.07
3.13 ‡
CEE Trial
The estimated absolute excess risk may differ slightly from the absolute excess risk derived from the differences in cases per 100 person-years between active hormone
and placebo groups. Estimated absolute excess risk was per 10 000 person-years calculated as [annualized percentage in the placebo group(hazard ratio in the pla-
cebo group−1)]1000. Error bars indicate 95% confidence intervals, estimated using bootstrap methods. CEE indicates conjugated equine estrogens; CHD, coronary
heart disease; MPA, medroxyprogesterone acetate.
*P=.03 compared with the age group of 50 to 59 years.
†P=.02 compared with the age group of 50 to 59 years.
‡P=.01 compared with the age group of 50 to 59 years.
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tenuated after excluding women older
than 60 years in the years since meno-
pause analyses) implies that, at a mini-
mum, screening and treatment of risk
factors for strokewould be advisable be-
fore considering hormone therapy.
For CEEMPA, the risk of breast
cancer also needs to be considered. In
women with less than 10 years since
Figure 2. Estimated Absolute Excess Risk per 10 000 Person-Years by Years Since Menopause at Baseline
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Estimated Absolute Excess Risk
per 10 000 Person-Years
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Cases per
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Placebo
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Estimated Absolute Excess Risk
per 10 000 Person-Years
0 40 80 120–40
Cases per
100 Person-Years
CEE +
MPA
0.19
0.40
0.79
0.15
0.35
0.57
0.24
0.48
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1.04
1.91
3.05
Placebo
0.23
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0.49 †
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1.68
2.75
CEE + MPA Trial
The estimated absolute excess risk may differ slightly from the absolute excess risk derived from the differences in cases per 100 person-years between active hormone
and placebo groups. Estimated absolute excess risk per 10 000 person-years calculated as [annualized percentage in the placebo group(hazard ratio in the placebo
group−1)]1000. Error bars indicate 95% confidence intervals, estimated using bootstrap methods. CEE indicates conjugated equine estrogens; CHD, coronary heart
disease; MPA, medroxyprogesterone acetate.
*P=.03 compared with the less than 10 years since menopause group.
†P=.04 compared with the less than 10 years since menopause group.
Table 6. Cardiovascular and Global Index Events in Subgroup of Participants with Moderate or Severe Vasomotor Symptoms at Baseline in the
Combined Trials
Age Group at Randomization
P Value
50-59 y 60-69 y 70-79 y
No. of Cases
HR
(95% CI)*
No. of Cases
HR
(95% CI)*
No. of Cases
HR
(95% CI)*
Hormone
Therapy
(n = 1097)
Placebo
(n = 1030)
Hormone
Therapy
(n = 691)
Placebo
(n = 665)
Hormone
Therapy
(n = 197)
Placebo
(n = 196) Trend†
Interaction
With
Vasomotor
Symptoms‡
CHD§ 17 19 0.86
(0.44-1.65)
31 25 1.20
(0.70-2.04)
27 6 5.08
(2.08-12.40)
.01 .04
Stroke 14 11 1.09
(0.49-2.43)
16 20 0.75
(0.39-1.45)
12 3 3.94
(1.09-14.23)
.28 .34
Total mortality 20 22 0.85
(0.46-1.56)
35 27 1.27
(0.77-2.12)
24 15 1.56
(0.81-3.00)
.22 .72
Global index  69 66 0.98
(0.70-1.38)
88 85 1.02
(0.75-1.37)
62 32 2.10
(1.35-3.27)
.02 .15
Abbreviations: CHD, coronary heart disease; CI, confidence interval; HR, hazard ratio.
*Cox regression models stratified according to prior cardiovascular disease and randomization status in the Dietary Modification Trial.
†Test for trend (interaction) using age as continuous (linear) form of categorical coded values. Cox regression models stratified according to active vs placebo and trial, including
terms for age and the interaction between trials and age.
‡Likelihood ratio test for 3-way interaction among hormone therapy, age, and vasomotor symptoms (none vs mild vs moderate or severe).
§Defined as CHD death, nonfatal myocardial infarction, or definite silent myocardial infarction (Novacode 5.1 or 5.2).
Defined as CHD, stroke, pulmonary embolism, breast cancer, colorectal cancer, endometrial cancer for CEE plus MPA trial only, hip fracture, or death from other causes.
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menopause, therewere 72 (0.32%) cases
ofbreast cancerwhile takingCEEMPA
compared with 57 (0.28%) cases while
taking placebo (HR, 1.19; 95%CI, 0.84-
1.70). By contrast, the increasing abso-
lute risks of CHD in older women or
women more distant from menopause
(mostmarked inwomenaged70years
or 20 years past menopause), to-
getherwith their increasedrisksof stroke,
breast cancer, and venous thromboem-
bolism, would in general contraindi-
cate the use of hormones for disease pre-
vention in these groups.
The findings for vasomotor symp-
toms are intriguing and of potential im-
portance to clinicians but need confir-
mation. The higher risks in women
more distant from menopause ap-
peared to be concentrated in the small
subset of women with moderate or se-
vere vasomotor symptoms. It is pos-
sible that vasomotor symptoms in re-
cently menopausal women represent
the reaction of vessels with normal en-
dothelial function to estrogen with-
drawal but persistent symptoms may
signify something different in older
women. If confirmed elsewhere (eg, by
reanalyses of existing observational
studies and clinical trials), the clinical
implication might be that while treat-
ment of vasomotor symptomswith hor-
mone therapy in younger women re-
mains an option, the reverse might
apply to olderwomen. Rather, the pres-
ence of moderate or severe vasomotor
symptoms at older agesmight signal the
need for identification and treatment of
risk factors for CHD. Although CHD
risk factors were more frequent in
women with vasomotor symptoms,
analyses adjusting for these factors did
not change the trend statistic, suggest-
ing that hormone therapy interactions
with other unmeasured risk factors in
womenwith vasomotor symptomsmay
underlie the increasing risk in women
more distant from menopause.
The current analyses are most perti-
nent to the effects of initiation of exog-
enous hormone use but also provide
some limited information regarding the
potential effects of prolonged use, tak-
ing into account indicators of hor-
mone status at trial enrollment.Within
the relatively short trial durations, CHD
risk related to hormone therapy ap-
peared to decrease over time. How-
ever, the significance of this trend over
time depends on both the initial in-
crease in risk, as well as the subsequent
decrease, and hence may partially rep-
resent a survivor effect. In addition, the
decreasing risk is confounded by dimin-
ishing compliance over time.Current or
past hormone users and never users ap-
peared to have similar trends toward in-
creasing risks by years since meno-
pauseduring the trial, providing indirect
evidence that longer duration of use is
not protective. It is not feasible to test
hormone effects over very long periods
of use in clinical trials, and observa-
tional studieshaveyieldedconflicting re-
sults.16,20Unlike statindrugs,whichhave
beneficial effects for both atherosclero-
sis and clinical events irrespective of the
underlying state of the arteries,21,22 hor-
mone therapy has a putative beneficial
effect onearly atherosclerosis,5,6 no effect
on advanced atherosclerosis,23,24 and an
early increase in risk of CHD events
when advanced atherosclerosis may be
present.2,3,25 Because age-related pro-
gression of atherosclerosis is likely to
continue even in the face of hormone
therapy, use over decades could poten-
tially result in an eventual increase in
CHD events. Hence, even if ongoing
imaging trials confirm a slowing of early
atherosclerosis,26,27 it would be unwise
to extrapolate such findings to clinical
benefit with continued use into old age.
These analyses are based on system-
atically ascertained outcomes in a set-
Table 7. Cardiovascular and Global Index Events in Subgroup of Participants With Moderate or Severe Vasomotor Symptoms at Baseline in
the Combined Trials
Years Since Menopause
P Value
10 10-19 20
No. of Cases
HR
(95% CI)*
No. of Cases
HR
(95% CI)*
No. of Cases
HR
(95% CI)*
Hormone
Therapy
(n = 833)
Placebo
(n = 757)
Hormone
Therapy
(n = 557)
Placebo
(n = 555)
Hormone
Therapy
(n = 440)
Placebo
(n = 459) Trend†
Interaction
With
Vasomotor
Symptoms‡
CHD§ 13 17 0.84
(0.40-1.77)
17 13 1.38
(0.63-3.00)
39 16 2.76
(1.53-4.97)
.01 .06
Stroke 10 3 3.36
(0.92-12.24)
13 11 1.02
(0.44-2.37)
16 16 0.92
(0.44-1.93)
.31 .59
Total mortality 14 16 0.93
(0.44-1.96)
17 15 1.21
(0.58-2.51)
42 29 1.60
(0.99-2.60)
.14 .41
Global index  55 47 1.15
(0.77-1.71)
59 47 1.23
(0.82-1.84)
85 72 1.30
(0.94-1.80)
.30 .48
Abbreviations: CHD, coronary heart disease; CI, confidence interval; HR, hazard ratio.
*Cox regression models stratified according to prior cardiovascular disease and randomization status in the Dietary Modification Trial.
†Test for trend (interaction) using years since menopause as continuous (linear) form of categorical coded values. Cox regression models stratified according to active vs placebo
and trial, including terms for years since menopause and the interaction between trials and years since menopause.
‡Likelihood ratio test for 3-way interaction among hormone therapy, years since menopause, and vasomotor symptoms (none vs mild vs moderate or severe).
§Defined as CHD death, nonfatal myocardial infarction, or definite silent myocardial infarction (Novacode 5.1 or 5.2).
Defined as CHD, stroke, pulmonary embolism, breast cancer, colorectal cancer, endometrial cancer for CEE plus MPA trial only, hip fracture, or death from other causes.
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ting of randomized controlled trials,
thus avoiding some of the potential
biases of observational studies. The
conclusions relating to harm in
women more distant from menopause
are more robust because of the larger
numbers of clinical events. The con-
clusions based on the analyses of
women closer to menopause are less
robust due to smaller numbers, as are
the analyses involving vasomotor
symptoms. Time of menopause may
not be accurately ascertained in
women who have undergone a hyster-
ectomy. Nonadherence may have
affected the results. At the end of the
trials, 54% of participants were no
longer taking CEE and 42% were no
longer taking CEEMPA. The results
are derived from relatively short dura-
tions of treatment but the average of 4
to 5 years of receiving treatment in the
trials is longer than most women
would need for treatment of vasomo-
tor symptoms. Multiple statistical tests
were performed, raising a distinct pos-
sibility that several of the positive find-
ings occurred by chance. The possibil-
ity of type I error is increased by the
fact that these analyses were partly
stimulated by the initial findings from
the trials. The results are dependent
on the analytic approach used, which
differs in this compared with previous
publications from the WHI trials. In
previous WHI studies using continu-
ous variables, the significance of the
interaction of years since hysterec-
tomy on CHD in the trial of CEE was
P=.06 compared with P=.15 for years
since menopause in the current analy-
sis using coded variables.3 In the trial
of CEEMPA, the significance for
years since menopause changed from
P= .33 to P= .05.4 Only one form of
oral estrogen and one form of oral
progestin taken daily were included in
the trials, and it may be that different
results would have been obtained if
other regimens (eg, transdermal estra-
diol, progesterone, or cyclic therapy)
were tested.
These analyses, although not defini-
tive, suggest that the health conse-
quences of hormone therapy may vary
bydistance frommenopause,withnoap-
parent increase in CHD risk for women
close tomenopause, andparticularlyhigh
risks in women who are distant from
menopause and have vasomotor symp-
toms. We did not identify any sub-
group with reduced risk of CHD, al-
though total mortality was reduced
amongwomen aged 50 to 59 years. The
findings regarding potential modifying
effects of vasomotor symptomswarrant
further study. The absence of excess ab-
solute risk of CHD and the suggestion
of reduced total mortality in younger
womenoffers somereassurance thathor-
mones remaina reasonableoption for the
short-term treatment of menopausal
symptoms, but does not necessarily im-
ply an absence of harm over prolonged
periods of hormoneuse. In contrast, risk
of stroke did not depend on years since
menopause or the presence of vasomo-
tor symptoms. The findings are consis-
tentwith current recommendations that
hormone therapy be used in the short-
term for relief of moderate or severe va-
somotor symptoms, butnot in the longer
termforpreventionof cardiovasculardis-
ease.28,29
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Phosphodiesterase Type-5 Inhibitors
and the Reemerging HIV Epidemic
To the Editor: The Commentary by Dr Jaffe and colleagues1
addressed the reemerging human immunodeficiency virus
(HIV) epidemic among men who have sex with men in the
United States. The authors describe substance abuse, particu-
larlymethamphetamines and alcohol, as oneof the factors that
contribute to unsafe sexual behaviors. Important substances
of abuse thatwerenotmentioned in theCommentary arephos-
phodiesterase type-5 inhibitors: sildenafil, vardenafil, and tad-
alafil. Phosphodiesterase type-5 inhibitors are indicated for the
treatment of impotence but can enhance erectile function in
the absence of clinical impotence and are often used in com-
bination with other recreational drugs.2
Inmultiple surveys ofUSmenwhohave sexwithmen, cur-
rent or recent sildenafil use (with and without concomitant
illicit drug use) was reported by 6% to 31% of respondents
and was associated with increased rates of high-risk behav-
iors (eg,unprotectedanal intercourse,HIVserodiscordantpart-
ners, and methamphetamine use) and diagnosis of sexually
transmitted infections, including early syphilis andHIV.3More
recent data have corroborated those findings.4 Discussion of
phosphodiesterase type-5 inhibitor abuse in the context of the
US HIV epidemic is warranted because at the point of pre-
scribing a phosphodiesterase type-5 inhibitor, clinicians can
initiate risk reduction interventions, including sexually trans-
mitted infection and HIV screening.5 In addition, we believe
that federal agencies should carefullymonitor theuse andmar-
keting of phosphodiesterase type-5 inhibitors and work to-
gether to limit the effects of these drugs on the reemerging
HIV epidemic and other sexually transmitted infections.5
Todd Hulgan, MD, MPH
todd.hulgan@vanderbilt.edu
Vanderbilt University School of Medicine
Nashville, Tennessee
Jeffrey D. Klausner, MD, MPH
San Francisco Department of Public Health
University of California, San Francisco
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This letter was shown to Dr Jaffe, who declined to reply on behalf of the
authors. —ED.
CORRECTION
Incorrect Number: In the Original Contribution entitled “Postmenopausal Hor-
mone Therapy and Risk of Cardiovascular Disease by Age and Years Since Meno-
pause” published in the April 4, 2007, issue of JAMA (2007;297[13]:1465-
1477), a number was incorrectly reported in the abstract and in Table 3. On page
1465, the first sentence in the Results section of the abstract should be “In the
combined trials, there were 396 cases of CHD and 327 cases of stroke in the hor-
mone therapy group vs 370 cases of CHD and 239 cases of stroke in the placebo
group.” In Table 3, first line of the table, “CHD§,” in second column under “Pla-
cebo,” the values should be changed from “379 (0.44)” to “370 (0.44).”
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